-
Lumacaftor (VX-809) is a
pharmaceutical drug that acts as a
chaperone during protein folding and
increases the
number of CFTR
proteins that are trafficked...
-
Lumacaftor/ivacaftor, sold
under the
brand name
Orkambi among others, is a
combination of
lumacaftor and
ivacaftor used to
treat people with
cystic fibrosis...
-
cases of
cystic fibrosis. It is also
included in
combination medications,
lumacaftor/ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor...
- year.
Vertex also
studied ivacaftor in
combination with
another drug (
lumacaftor) for the most
common mutation in
cystic fibrosis (CF),
known as F508del...
- States. In July 2015, the U.S. Food and Drug
Administration approved lumacaftor/ivacaftor. In 2018, the FDA
approved the
combination ivacaftor/tezacaftor;...
-
Iobenguane I 131
Progenics Pharmaceuticals pheochromocytoma or
paraganglioma Lumacaftor/ivacaftor
Vertex Pharmaceuticals cystic fibrosis Mogamulizumab-kpkc Kyowa...
-
combinations R07AX01
Nitric oxide R07AX02
Ivacaftor R07AX30
Ivacaftor and
lumacaftor R07AX31
Ivacaftor and
tezacaftor R07AX32 Ivacaftor,
tezacaftor and elexacaftor...
- impossible.
Negulescu also led the
discovery of
another cystic fibrosis drug,
lumacaftor,
which is
known as a "corrector" as it acts as a
chaperone to help the...
- to
subsequent discovery of Orkambi, the
combination of
Ivacaftor and
Lumacaftor(VX-809),
approved to
treat CF in
people with two
copies of the F508del...
-
people in the
world to be
treated by the
second new
cystic fibrosis drug
lumacaftor/ivacaftor
which treats the most
common mutation of CF. The drug has proven...
